Has a higher incidence of extrapyramidal side effects than the other atypical antipsychotics, but still less than that seen with typical antipsychotics.<ref name = "CNS Drugs"/><ref name = Martindale>{{cite book|title=Perospirone Hydrochloride|work=Martindale: The Complete Drug Reference|publisher = The Royal Pharmaceutical Society of Great Britain|date=23 September 2011|accessdate=3 November 2013|url=http://www.medicinescomplete.com/mc/martindale/current/15232-k.htm}}</ref> A trend was observed in a clinical trial comparing mosapramine with perospirone that favoured perospirone for producing less prominent extrapyramidal side effects than mosapramine although statistical significant was not reached.<ref name = "Mos" /> It may produce less [[QT interval]] prolongation than [[zotepine]], as in one patient who had previously been on zotepine switching to perospirone corrected their prolonged QT interval.<ref>{{cite journal|last=Suzuki|first=Y|author2=Watanabe, J |author3=Sugai, T |author4=Fukui, N |author5=Ono, S |author6=Tsuneyama, N |author7=Saito, M |author8= Someya T |title=Improvement in QTc prolongation induced by zotepine following a switch to perospirone|journal=Psychiatry and Clinical Neurosciences|date=March 2012|volume=66|issue=3|page=244|doi=10.1111/j.1440-1819.2012.02321.x|pmid=22443250|url=http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1819.2012.02321.x/pdf}}</ref> It also tended to produce less severe [[extrapyramidal side effects]] than haloperidol in a clinical trial comparing the two (although statistical significance was not reached).<ref name = "Hal" />

 

